26 October 2015 - Endo Pharmaceuticals Inc., and BioDelivery Sciences International, Inc., announced today that the U.S. FDA has approved Belbuca (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

For more details, go to: http://www.endo.com/news-events/press-releases?c=123046&p=irol-newsArticle&ID=2100937